NCT05725200View on ClinicalTrials.gov

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

December 31, 2038

Study Completion Date

December 31, 2040

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Alectinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.

DRUG

Cetuximab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Crizotinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Dasatinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Everolimus

Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.

DRUG

Encorafenib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Gemcitabine

Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.

DRUG

Idelalisib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Larotrectinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Methotrexate

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Palbociclib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Panobinostat

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Pembrolizumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Petrozumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Trastuzumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Talazoparib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Venetoclax

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

Trial Locations (1)

0379

RECRUITING

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER